- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: filgrastim and pediatric.
Displaying page 1 of 1.
EudraCT Number: 2014-001772-55 | Sponsor Protocol Number: XM02-ONC-201 | Start Date*: 2015-01-26 | |||||||||||
Sponsor Name:TEVA Pharmaceutical Industries Ltd | |||||||||||||
Full Title: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 μg/kg tbo-filgrastim... | |||||||||||||
Medical condition: Chemotherapy induced Neutropenia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) PL (Completed) RO (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000087-34 | Sponsor Protocol Number: XM22-08 | Start Date*: 2015-06-05 | ||||||||||||||||
Sponsor Name:Merckle GmbH | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Lipegfilgrastim 100 μg/kg B... | ||||||||||||||||||
Medical condition: Neutropenia in pediatric patients diagnosed with Ewing family of Tumors or rhabdomyosarcoma receiving chemotherapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) LT (Completed) SK (Completed) CZ (Completed) BG (Completed) DE (Ongoing) ES (Completed) RO (Completed) PL (Completed) BE (Completed) HR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001430-14 | Sponsor Protocol Number: peg-filgrastim Vs filgrastim nel t | Start Date*: 2007-02-19 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA | |||||||||||||
Full Title: Peg-filgrastim Vs filgrastrim in pediatric patients. | |||||||||||||
Medical condition: haematologic malignant tumors | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002697-45 | Sponsor Protocol Number: ACT15378 | Start Date*: 2019-03-04 | ||||||||||||||||
Sponsor Name:Sanofi-aventis recherche & developpement | ||||||||||||||||||
Full Title: Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Year... | ||||||||||||||||||
Medical condition: Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination with Chemotherapy in Pediatric Patients from 28 Days to Less than 18 Year... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) NO (Completed) FI (Completed) DK (Ongoing) FR (Completed) NL (Completed) PT (Ongoing) BE (Completed) DE (Completed) CZ (Completed) GR (Completed) Outside EU/EEA IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005432-28 | Sponsor Protocol Number: NEUGR-005 | Start Date*: 2013-10-15 | |||||||||||
Sponsor Name:Teva Pharmaceuticals Industries Ltd. | |||||||||||||
Full Title: An open label, randomized, active controlled, dose finding study to evaluate the pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim at doses of 300 μg/kg and 670 μg/kg in pediat... | |||||||||||||
Medical condition: Neutropenia induced by chemotherapy in patients with solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Completed) BG (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002172-39 | Sponsor Protocol Number: VX21-CTX001-141 | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:VERTEX PHARMACEUTICALS INCORPORATED | |||||||||||||
Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent ß-Thalassemia | |||||||||||||
Medical condition: Transfusion-Dependent ß Thalassemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004498-29 | Sponsor Protocol Number: 20190360 | Start Date*: 2022-01-13 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor... | |||||||||||||
Medical condition: Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Ongoing) SE (Ongoing) AT (Ongoing) FI (Ongoing) ES (Ongoing) DK (Ongoing) IT (Ongoing) BE (Ongoing) HU (Ongoing) BG (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003444-20 | Sponsor Protocol Number: AAML1421 | Start Date*: 2017-08-24 | |||||||||||
Sponsor Name:Children's Oncology Group | |||||||||||||
Full Title: A Phase 1/2 Study of CPX-351 Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML). | |||||||||||||
Medical condition: Acute myeloid leukemia recurrent | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004554-14 | Sponsor Protocol Number: PIX111 | Start Date*: 2016-11-24 | |||||||||||
Sponsor Name:CTI BioPharma Corp. | |||||||||||||
Full Title: A Phase 1, Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients with Relapsed or Refractory Cancer | |||||||||||||
Medical condition: Relapsed or refractory solid tumors (excluding those with CNS tumors) or lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016075-30 | Sponsor Protocol Number: GIMEMA LAL1308 | Start Date*: 2010-07-09 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL`ADULTO | |||||||||||||
Full Title: Therapy of the Young Adult Acute Lymphoblastic Leukemia (ALL): treatment intensification of the pediatric protocol AIEOP LLA-2000 | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005923-42 | Sponsor Protocol Number: TACL2008-002/ITCC033 | Start Date*: 2013-04-09 | ||||||||||||||||
Sponsor Name:TACL | ||||||||||||||||||
Full Title: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL, POETIC and ITCC | ||||||||||||||||||
Medical condition: relapsed T-ALL, T-NHL | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) AT (Prematurely Ended) GB (Completed) IT (Ongoing) FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000415-87 | Sponsor Protocol Number: 208467 | Start Date*: 2019-12-11 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||||||||||||||||||
Full Title: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ES... | ||||||||||||||||||
Medical condition: Synovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) FR (Ongoing) ES (Ongoing) DE (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.